TTF1 and adenocarcinoma: PD-L1 expression was distributed as <1% in 31.7%, 1–49% in 38.3%, and ≥50% in 30.0%, with thyroid transcription factor-1 (TTF-1) positive in 69.2% of adenocarcinomas.